title: [Clinical observation on LOP regimen combined with IMRT treatment for early nasal NK/T cell lymphoma].
abstract: Objective:To observe the clinical efficacy and safety of the LOP regimen (L-asparaginase, vincristine, dexamethasone) combined with intensity modulated radiation therapy(IMRT)in the treatment of early nasal NK/T cell lymphoma.Method:Clinical data of 65 patients with nasal NK/T cell lymphoma treated with LOP chemotherapy combined with IMRT at the Guizhou Province Tumor Hospital between March 2010 and January 2015 were retrospectively analyzed.Results:Among the 65 patients, 39 cases obtained complete remission (CR), 18 cases obtained partial remission(PR), 1 case obtained stable disease (SD), 7 cases had progressive disease(PD). The objective response rate (ORR) was 87.7%, the disease control rates (DCR) was 89.2%. The DCR was lower in the patients with B symptoms or over age of 60. Patients with super cavity obtained a worse progression-free survival(PFS). The 1-, 2-, 3-year PFS were 91.7%, 74.8% and 61.3%, the overall survival(OS) were 91.8%, 81.3% and 78.9%, respectively. Main adverse reactions were myelosuppression, gastrointestinal reaction, hepatic lesion, hypoproteinemia, percutaneous reaction and oral mucosa reaction. No severe pancreatitis, severe anaphylaxis and toxic related death were observed.Conclusion:The LOP regimen combined with IMRT treatment for nasal NK/T cell lymphoma may have a good therapeutic effect, low toxicity, and good tolerance.
authors.affiliation: Department of Lymphoma, Affiliated Hospital of Guizhou Medical University, Guizhou Province Tumor Hospital, Guiyang 550001, China.
authors.forename: Y F
authors.initials: YF
authors.lastname: Hu
authors.forename: Y H
authors.initials: YH
authors.lastname: Huang
authors.forename: T
authors.initials: T
authors.lastname: Wu
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.forename: X M
authors.initials: XM
authors.lastname: Liu
authors.forename: Y
authors.initials: Y
authors.lastname: Song
authors.forename: J Y
authors.initials: JY
authors.lastname: Gan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D007694:Killer Cells, Natural; D016399:Lymphoma, T-Cell; D009666:Nose; D009669:Nose Neoplasms; D050397:Radiotherapy, Intensity-Modulated; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate
keywords: Adverse reactions; Dexamethasone; L-asparaginase; Lymphoma, extranodal NK-T-cell; Treatment outcome